There were 1,777 press releases posted in the last 24 hours and 430,119 in the last 365 days.

INSYS Therapeutics to Report Fourth Quarter 2017 Results on March 8

PHOENIX, Feb. 23, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2017 financial results on Thursday, March 8, after the U.S. financial markets close.

Following the release, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 5:00 p.m. Eastern Standard Time to discuss the results.

Interested parties can listen to the call live via the company’s website, https://www.insysrx.com/, on the Investors section Presentations & Events page; or by dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from outside the U.S.). A webcasted replay of the call will be available on the site a few hours after the event.

About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, the company is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.

CONTACT: Corporate Communications Investor Relations
  Joe McGrath Jackie Marcus or Chris Hodges
  INSYS Therapeutics Alpha IR Group
  480-500-3101 312-445-2870
  jmcgrath@insysrx.com INSY@alpha-ir.com

Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.